Malaria Treatment Global Market Report 2024

The malaria treatment market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.57 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period can be attributed to several key factors. These include the discovery of effective drugs for treating malaria, concerted efforts in vector control, global health initiatives aimed at combating malaria, advancements in scientific research contributing to better understanding and treatment options, and the development of health infrastructure to support malaria prevention and treatment efforts. Collectively, these factors played a crucial role in fostering growth and progress in addressing the challenges posed by malaria during the historical period.

The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The projected expansion during the forecast period can be ascribed to factors such as the monitoring of drug resistance, the impact of climate change, the adoption of precision medicine and genomic approaches, reforms in healthcare financing, and the integration of digital health solutions. Key trends anticipated during the forecast period encompass enhancements in epidemiological surveillance, the integration of alternative medicine, advancements in malaria vaccine development, the implementation of data-driven treatment programs, and the initiation of education and training initiatives.

The anticipated surge in the prevalence of malaria is poised to drive the expansion of the malaria treatment market in the coming years. Malaria, a potentially life-threatening mosquito-borne ailment caused by the Plasmodium parasite, manifests with recurrent fever and flu-such as symptoms. This upswing in malaria cases is attributable to factors such as poverty, limited access to healthcare services, climate change, absence of robust malaria control measures, and emerging drug resistance. Malaria treatment plays a pivotal role in effectively managing and curing infections caused by the Plasmodium parasite.

The growth of the malaria treatment market is bolstered by the escalation in healthcare spending. Healthcare spending, denoting the overall financial resources allocated to the healthcare sector within a specific region, country, or organization, is instrumental in efficiently managing and preventing the proliferation of the disease. This involves ensuring access to timely diagnosis, antimalarial medications, and preventive measures. As an illustrative example, a report from the American Medical Association in March 2023 revealed a 2.7% increase in health spending in the United States in 2021, reaching $4.3 trillion, equivalent to $12,914 per capita. Consequently, the upsurge in healthcare spending is a key driver fueling the growth of the malaria treatment market in the foreseeable future.

The malaria treatment market is witnessing a notable trend with the emergence of novel diagnostic technologies, a development gaining traction among companies in the industry. To maintain their competitive edge, companies in the malaria treatment market are increasingly embracing innovative diagnostic malaria detection technologies. An example is Sysmex America Inc., a US-based developer and manufacturer of automated diagnostic technology, which introduced the XN-30 in October 2021. This automated hematology analyzer incorporates features such as a violet laser, specialized reagents, and advanced algorithms, enabling the differentiation of malarial strains such as P. falciparum and non-falciparum species, along with understanding their life cycle staging. Such advancements in detection contribute to the effective management of malaria treatment and patient recovery.

Major players in the malaria treatment market are adopting a strategic partnership approach to expedite the elimination of relapsing P. vivax malaria. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. An illustrative example is the collaboration between PATH, a US-based nonprofit global health organization, and Medicines for Malaria Venture (MMV), a Switzerland-based foundation specializing in antimalarial drug research and development. This partnership aims to advance the development of quality-assured, child-friendly treatments for relapse prevention, generate evidence to support malaria-endemic countries in developing and implementing new strategies for P. vivax malaria elimination, and promote the development and availability of quality-assured medicines and diagnostics for P. vivax.

In November 2022, Novartis AG, a Switzerland-based pharmaceutical and healthcare company, joined forces with Medicines for Malaria Venture to conduct phase III clinical trials for a novel ganaplacide and lumefantrine-SDF medication combination targeting malaria in both adults and children. Medicines for Malaria Venture (MMV), as a Switzerland-based non-profit organization focused on antimalarial drug research and development, underscores the collaborative efforts within the industry to advance malaria treatment solutions.

Major companies operating in the malaria treatment market report are Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC., Takeda Pharmaceutical Company Limited, Sumitomo Chemical Co. Ltd., Viatris Inc., Mylan N.V., Sandoz International GmbH, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., Medicines Sans Frontières (Doctors Without Borders), Strides Pharma Science Limited, Swiss Tropical and Public Health Institute (Swiss TPH), Aprecia Pharmaceuticals LLC, AdvaCare Pharma USA LLC, Medicines for Malaria Venture (MMV), VLP Therapeutics LLC, Actiza Pharmaceutical Private Limited.

Middle East and Africa was the largest region in the malaria treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary components of malaria treatment include prescription medications, vaccines, diagnostic tests, and other therapeutic approaches. Prescription medications are pharmaceuticals that require a valid prescription from a healthcare professional. In the context of malaria treatment, these drugs are essential for providing targeted and regulated therapy to combat the infection. They can be administered through oral, parenteral, and intravenous routes and are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels serve hospitals, specialty clinics, home care settings, and other end users, ensuring a comprehensive reach for malaria treatment options.

The malaria treatment market research report is one of a series of new reports that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.